Migraine drug shows promise for rare facial nerve pain
NCT ID NCT04158752
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug that blocks a pain-signaling protein (CGRP) in 26 adults with trigeminal or glossopharyngeal nerve pain caused by small fiber neuropathy or fibromyalgia. The goal was to see if it reduces pain and the need for other pain medications, while checking for side effects. The drug is already approved for migraines, so researchers wanted to see if it could help these other painful conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLOSSOPHARYNGEAL NEURALGIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University
Durham, North Carolina, 27705, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Pain relief showdown: one drug vs. two for facial nerve pain
- New combo therapy aims to calm face pain attacks
- Laser showdown: which light therapy zaps facial pain best?
- Massive study aims to predict brain surgery success
- Magnetic pulses to the brain may ease stubborn nerve pain
- AI and VR join forces to fight severe facial pain